Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2017 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Depreciation & Amortization (CF) of $29000.0 for Q1 2026, up 31.82% year-over-year from $22000.0 in Q1 2025, and up 11.54% quarter-over-quarter from $26000.0 in Q4 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $29000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 31.82% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $112000.0 (up 33.33% YoY), while the FY2025 annual figure was $105000.0, up 23.53% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $29000.0, up from $26000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $94000.0 in Q3 2022, with the low at $20000.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $29000.0 (2025), against an average of $43352.9.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) slumped 70.21% in 2023, then surged 38.1% in 2025.
- Corvus Pharmaceuticals' Depreciation & Amortization (CF) stood at $94000.0 in 2022, then plunged by 70.21% to $28000.0 in 2023, then retreated by 28.57% to $20000.0 in 2024, then increased by 30.0% to $26000.0 in 2025, then advanced by 11.54% to $29000.0 in 2026.
- Business Quant data shows CRVS's Depreciation & Amortization (CF) at $29000.0 in Q1 2026, $26000.0 in Q4 2025, and $28000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | 34,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 36,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 94,000.00 |
| Sep 30, 2022 | 94,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 87,000.00 |
| Dec 31, 2021 | 93,000.00 |
| Sep 30, 2021 | 108,000.00 |